Abatacept
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Active Polyarticular Juvenile Idiopathic Arthritis
Conditions
Active Polyarticular Juvenile Idiopathic Arthritis
Trial Timeline
Aug 30, 2013 → Feb 1, 2023
NCT ID
NCT01844518About Abatacept
Abatacept is a phase 3 stage product being developed by Bristol Myers Squibb for Active Polyarticular Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01844518. Target conditions include Active Polyarticular Juvenile Idiopathic Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05170672 | Pre-clinical | Completed |
| NCT05981976 | Phase 1 | Completed |
| NCT04925375 | Phase 2 | Recruiting |
| NCT04472494 | Phase 2 | Terminated |
| NCT04477642 | Phase 1/2 | Withdrawn |
| NCT03924401 | Phase 2 | Active |
| NCT03882008 | Approved | Completed |
| NCT03669861 | Phase 2 | Completed |
| NCT03714022 | Phase 1 | Completed |
| NCT03084419 | Phase 2 | UNKNOWN |
| NCT03215927 | Phase 2 | Completed |
| NCT02915159 | Phase 3 | Completed |
| NCT02805010 | Phase 1 | UNKNOWN |
| NCT02037737 | Pre-clinical | Completed |
| NCT02592798 | Phase 2 | Completed |
| NCT02598466 | Pre-clinical | Completed |
| NCT02281058 | Phase 1 | UNKNOWN |
| NCT02078882 | Approved | Completed |
| NCT01954979 | Phase 1 | Completed |
| NCT02169544 | Pre-clinical | Completed |
Competing Products
20 competing products in Active Polyarticular Juvenile Idiopathic Arthritis